TPC Safety Study Published in JCO Precision Oncology
Multi-Omics Guidance Safe for Advanced Melanoma Treatment
The Tumor Profiler Consortium celebrates the publication of a comprehensive safety analysis demonstrating that multi-omics-guided therapy selection is safe and feasible for patients with advanced melanoma. The study, published in JCO Precision Oncology, represents the first comparative safety analysis of multi-omics informed therapies.
7th Zurich Precision Oncology Conference 2026
Call for Abstracts Open
The Tumor Profiler Consortium invites the TPC community to participate in the 7th Zurich Precision Oncology Conference 2026, hosted for the first time jointly by the Comprehensive Cancer Center Zurich (CCCZ), The LOOP Zurich, and the Tumor Profiler Center.
Multi-Omics Profiling Proves Cost-Effective
Multi-Omics Profiling Proves Cost-Effective: TPC Melanoma Study Published in npj Precision Oncology
A comprehensive cost analysis from the Tumor Profiler melanoma project has been accepted for publication in npj Precision Oncology. The study demonstrates that multi-omics-guided treatment decisions do not lead to significantly higher treatment costs compared to standard care, addressing a key concern in precision oncology implementation.
Navignostics Wins Swiss Technology Award in Start-ups Category
Navignostics Wins Swiss Technology Award in Start-ups Category
Navignostics, a precision oncology company with roots in TPC-affiliated research, has been awarded the prestigious Swiss Technology Award 2025 in the Start-ups/Rising Stars category. The Tumor Profiler Center extends warm congratulations to the Navignostics team for this outstanding achievement.
Driving Precision Oncology Forward - New Research Initiatives in Zurich
Zurich Expands Precision Oncology in a Pioneering Way – Four New Research Initiatives to Launch in 2026
With a targeted expansion of precision oncology, University of Medicine Zurich (UMZH) is strengthening its leading role in Swiss cancer medicine. Beginning 1 January 2026, four new highly innovative research projects will launch, further paving the way toward individually tailored cancer therapies. The goal is to sustainably improve care for patients in Zurich and across Switzerland.
The University of Medicine Zurich (UMZH) is making targeted investments in strategic centers to strengthen Zurich as a hub for research and innovation and to accelerate the translation of new medical approaches into patient care. Supported institutions include the Comprehensive Cancer Center Zurich (CCCZ), the Tumor Profiler Center (TPC) and The LOOP Zurich. These centers unite top expertise in precision medicine, oncology, data science and translational research, and play a vital role in developing and applying personalized diagnostics and treatment approaches in clinical practice.
Snijder Lab Wins Precision Medicine Award 2025
Snijder Lab Wins Precision Medicine Award 2025 for Pharmacoscopy Technology
The Tumor Profiler Consortium congratulates Prof. Berend Snijder and the Snijder Lab on receiving the Precision Medicine Award 2025 from Oxford Global for "Biggest Technology Impact of the year". The award recognises their pioneering work on pharmacoscopy, a functional precision medicine platform.
HistoPlexer: AI Model Trained on TPC Data Predicts Protein Expression from Routine Pathology
TPC Data Enables AI Model for Predicting Protein Expression from Standard Pathology Images
Research published in Nature Machine Intelligence demonstrates that multimodal data from the Tumor Profiler Center can train artificial intelligence models to predict spatially resolved protein expression patterns directly from routine histopathology slides. The study, published on August 4, 2025, presents HistoPlexer, a deep learning framework with potential to make advanced molecular profiling more accessible in precision oncology.
TPC Publishes Landmark Study in Nature Medicine
TPC Publishes Landmark Study in Nature Medicine on Multi-Omics Tumor Profiling for Melanoma
The Tumor Profiler Center is proud to announce the publication of groundbreaking research in Nature Medicine demonstrating the feasibility and clinical impact of multi-omics tumor profiling for guiding melanoma treatment. Published on May 27, 2025, this landmark study provides compelling real-world evidence for personalized cancer care.
